A Phase 4 interventional study of inclisiran sodium injection and Standard of Care in Coronary Heart Disease, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 19 sites in China. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-05-29.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 223 studies in Coronary Disease with a site in China — 68 open to participants now, 77 under way, 3 of them phase 3. Coronary Disease · China.
Among the 223 studies in Coronary Disease with a site in China, this one is the 25th largest by enrollment of the 141 interventional ones that give a count, is one of 20 that started in 2025, is one of 34 in phase 4, reaches primary completion later than 52 of the 76 other live ones, and was the 186th registered.
1,521 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.
Browse Coronary Disease studies →68 of the 223 studies in Coronary Disease with a site in China are open now. Recruiting first, the newest first:
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Gan Lijun · Sites in China
Ages 18+
Xia Liang · Sites in China
Ages 50–75
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 105 Coronary Disease studies recruiting now, 63 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
223 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 10 · Phase 4 34
First in 1999; this study’s year is marked. 20 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,590 is above the median of 160 across 779 interventional studies indexed under Coronary Disease.
Median enrollment 220 across the 141 interventional studies, 1,508 across the 82 observational. Of the 75 that completed or were terminated, 11 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 223 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 7 studies filed under Coronary Disease — fewer than ten, so there is no comparison to draw.
22 of the studies in Coronary Disease with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05997693Phase 3Weill Medical College of Cornell UniversityOne-Month DAPT in CABG Patients | 2027-01 |
| NCT06472908Phase 3Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyEfficacy and Safety of Colchicine After PCI | 2027-06-30 |
| NCT07259278China National Center for Cardiovascular DiseasesIntelligent Management Platform for Guiding Exercise Rehabilitation in Coronary Heart Disease Patients | 2026-11-30 |
| NCT07841275China Academy of Chinese Medical SciencesReal-World Effectiveness and Costs of Yiqi Fumai Lyophilized Injection in Coronary Heart Disease-Related Chronic Heart Failure | 2026-12 |
| NCT05397392Nanjing First Hospital, Nanjing Medical UniversityResearch on Optimal Diagnosis and Treatment of Cardiorenal Syndrome | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 223 studies in Coronary Disease with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The current study will be conducted to evaluate the real-world effectiveness of inclisiran relative to standard of care (SoC) in Chinese patients with coronary heart disease (CHD), not only with the low-density lipoprotein cholesterol (LDL-C) change in 1 year, but also the LDL-C Test on Target for 1 year. This study further aims to assess the adherence, treatment patterns and satisfaction, and safety of inclisiran among Chinese patients.
The study is a multicenter, randomized, parallel, open-label, pragmatic trial, to assess the effectiveness of inclisiran in the real-world compared to SoC, in patients with CHD in China who did not achieve LDL-C goal despite maximally tolerated statin therapy for ≥4weeks stable using. CHD patients include patients with acute coronary syndrome and patients with chronic coronary syndrome.
After granting informed consent, being screened, and confirmed eligible for the study, participants will be randomized to 2 arms (inclisiran or SoC) in a 1:1 ratio.
Following the randomization, participants start inclisiran or SoC adaptation (which means switching to or adding on another/other lipid-lowering therapies (LLT[s]). This start date is defined as Day 0.
During follow-up, each participant will follow routine care, and the results of LDL-C tests will be collected for each Visit (every 3 months), with an allowable window of ±1.5 months. Each patient will be followed up until his/her end of study (EOS), which is the earliest of the end of follow-up period (Visit 4: approximately 12 months following Day 0), lost to follow-up, consent withdrawal, death, and participating in another interventional trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The maximum tolerated dose of statins also includes patients with statin intolerance or .
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patients in the inclisiran group will receive inclisiran (may or may not plus cholesterol absorption inhibitor at the discretion of the treating physician).
Drug: inclisiran sodium injection
Patients in the SoC group will switch to/add on another/other LLT(s) at the discretion of the treating physician, as long as it is not inclisiran or an investigational drug.
Combination Product: Standard of Care
After randomization, patients in the inclisiran group will receive inclisiran sodium injection
After randomization switching to or adding on another/other lipid-lowering therapies
The percentage change in low-density lipoprotein cholesterol (LDL-C) level from baseline at 12 months, for the inclisiran group versus the standard of care (SoC) group
To evaluate the real-world effectiveness of inclisiran, on the change in LDL-C levels at Month 12, compared with SoC, in Chinese patients with coronary heart disease (CHD)
Time frame: 12 months
The proportion of participants with the 1-year LDL-C Test on Target ≥75%, for the inclisiran group versus the SoC group
To evaluate the real-world effectiveness of inclisiran, on the LDL-C Test on Target at Month 12, compared with SoC, in Chinese patients with CHD
Time frame: 12 months
The percentage change in LDL-C level from baseline at 3 months, 6 months, and 9 months, for the inclisiran group versus the SoC group
To evaluate the effectiveness of inclisiran on the change in LDL-C levels at Month 3, Month 6, and Month 9, compared with SoC
Time frame: At Month 3, Month 6 and Month 9
The proportion of participants with LDL-C <1.8 mmol/L at 12 months, for the inclisiran group versus the SoC group
To evaluate the effectiveness of inclisiran on LDL-C at goal at Month 12
Time frame: 12 months
To describe LDL-C Test on Target value during the 12 months after baseline, for the inclisiran group and the SoC group.
To evaluate the real-world effectiveness of inclisiran, on LDL-C Test on Target at 1 year, compared with the SoC group.
Time frame: 12 months
The percentage change in levels of total cholesterol, triglyceride, HDL-C, Lp(a), ApoA, and ApoB, from baseline at 3 months, 6 months, 9 months, and 12 months, for the inclisiran group versus the SoC group
To evaluate the effectiveness of inclisiran on the change in other parameters of the lipid profile at Month 3, Month 6, Month 9, and Month 12, compared with SoC
Time frame: At Month 3, Month 6, Month 9, and Month 12
Area under the curve (AUC) of LDL-C level versus time (from 0 months to 12 months), for the inclisiran group versus the SoC group
To evaluate the accumulated LDL-C in the inclisiran group and the SoC group
Time frame: Baseline, 12 months
The proportion of participants with PDCinclisiran≥80% in the inclisiran group and the proportion of participants with PDCnon-statin≥80% in the SoC group, at 3 months, 6 months, 9 months, and 12 months
To estimate the adherence to inclisiran and other non-statin lipid-lowering therapies (LLTs), as measured by the proportion of days covered (PDC), using prescription data
Time frame: At Month 3, Month 6, Month 9, and Month 12
The average number of days covered, of inclisiran in the inclisiran group and of non-statin lipid-lowering therapies (LLTs) in the SoC group, at 3 months, 6 months, 9 months, and 12 months
To estimate the adherence to inclisiran and other non-statin lipid-lowering therapies (LLTs), as measured by the proportion of days covered (PDC), using prescription data
Time frame: At Month 3, Month 6, Month 9, and Month 12
The average PDCinclisiran in the inclisiran group and the average PDCnon-statin in the SoC group, at 3 months, 6 months, 9 months, and 12 months
To estimate the adherence to inclisiran and other non-statin lipid-lowering therapies (LLTs), as measured by the proportion of days covered (PDC), using prescription data
Time frame: At Month 3, Month 6, Month 9, and Month 12
Age at randomization and age at first diagnosis of CHD
To describe the demographics and clinical characteristics of the inclisiran group and the SoC group.
Time frame: 12 months
Sex
To describe the demographics and clinical characteristics of the inclisiran group and the SoC group
Time frame: 12 months
Temperature
To describe the demographics and clinical characteristics of the inclisiran group and the SoC group
Time frame: 12 months
Respiratory rate
To describe the vital signs characteristics of inclisiran group and the SoC group. It will be measured manually or with an electrocardiogram monitor.
Time frame: 12 months
Blood pressure
To describe the demographics and clinical characteristics of the inclisiran group and the SoC group
Time frame: 12 months
Heart rate
To describe the demographics and clinical characteristics of the inclisiran group and the SoC group
Time frame: 12 months
Previous lipid-lowering therapies (LLTs), through Adherence Assessment Questionnaire (AAQ)
The AAQ is a generic instrument for assessing non-adherence (NA) in chronic conditions, consists of 11 items in total. Ten of these items are phrased as statements and use a 4-point Likert scale, offering the response options: Strongly agree, Generally agree, Generally disagree, and Strongly disagree. Each item is scored from 1 to 4, with a higher score indicating a greater likelihood of non-adherence.
Time frame: 12 months
Previous lipid-lowering therapies (LLTs), through Adherence Barriers Questionnaire (ABQ)
The ABQ consists of 16 items, each addressing a specific adherence barrier. All items are formulated as statements. A 4-point Likert scale is used, deliberately omitting a neutral response option to encourage decisive answers. The available response options are: Strongly agree, Generally agree, Generally disagree, and Strongly disagree. Each response is assigned a value from 1 to 4 or 4 to 1, depending on the wording of the item, ensuring that a higher score reflects a stronger influence of a specific barrier on the patient's perception. The total score ranges from 16 (minimum) to 64 (maximum).Based on patient responses, both a general ABQ score and item- or subscale-specific scores can be calculated, indicating the number and strength of adherence barriers experienced by a patient.
Time frame: 12 months
Dose, frequency, and treatment duration of inclisiran in the inclisiran group and of other LLTs in the SoC group
To describe the treatment patterns of inclisiran and other LLTs
Time frame: 12 months
LDL-C variability in the inclisiran group by average successive variability (ASV), coefficient of variation (CV), and variation independent of mean (VIM)
To evaluate LDL-C variability in the inclisiran group
Time frame: 12 months
Subsequent LLTs for participants who discontinued/switched the assigned treatment
To describe the treatment patterns of inclisiran and other LLTs
Time frame: 12 months
Concomitant lipid lowering treatments
To describe the treatment patterns of inclisiran and other LLTs
Time frame: 12 months
Treatment satisfaction from Treatment Satisfaction Questionnaire for Medication (TSQM)
This scale includes four dimensions: drug treatment effectiveness, adverse reactions, convenience, and overall satisfaction. Whether the patient has experienced adverse drug reactions is scored using "yes" and "no"; The adverse reaction dimension is evaluated using a Likert-5 scale, with scores ranging from 1 to 5 indicating "extremely dissatisfied" to "not dissatisfied at all"; The effectiveness, convenience, and overall satisfaction are rated on a Likert-7 scale, with scores ranging from 1 to 7 indicating "extremely dissatisfied" and "extremely satisfied", respectively. The standard score for each dimension is 100 points, and the higher the score, the higher the patient's satisfaction with drug treatment.
Time frame: At Month 6 and Month 12
The average PDCinclisiran in the inclisiran group and the average PDCnon-statin in the SoC group, from patient questionnaire data, at 3 months, 6 months, 9 months, and 12 months
To assess treatment satisfaction and adherence by questionnaires
Time frame: At Month 3, Month 6, Month 9, and Month 12
Incidence of adverse events (AEs), serious adverse events (SAEs)
To evaluate the safety of Inclisiran
Time frame: 12 months
Number of participants with relevant medical history
To describe the demographics and clinical characteristics of the inclisiran group and the SoC group
Time frame: 12 months
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Apr 2027, 22 months after the start.
Of 26 phase 4 interventional studies under Coronary Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 58. This study's planned 22 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inclisiran